Security
IGC Pharma, Inc. · IGC
IGCNYSE_AMERICANCommon stockCurrentCIK 1326205Updated Oct 23, 2026
Name history
India Globalization Capital, Inc. · through Mar 21, 2023
IGC price & chart
Loading TradingView…
AMEX:IGC on TradingView ↗About the company
IGC Pharma (NYSE American: IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer’s and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer’s dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With more than 30 patent filings, 12 patents granted and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.
In the news
No coverage from other publishers is available.
Seeking Alpha
IGC Pharma GAAP EPS of -$0.03 misses by $0.01, revenue of $0.27M beats by $0.17M ↗
IGC Pharma reports results ↗
SEC disclosures
IGC Pharma, Inc. files 8-K: Material Event ↗
Recent filings
Show 5 more recent filings
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities
Items 1.01, 3.02, 9.01
4 filing
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 1.01, 2.03, 9.01
10-Q filing
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities
Items 1.01, 2.03, 3.02, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 9,078,000Source | 11,259,000Source | 9,743,000Source | 10,369,000Source | 16,506,000Source | 7,943,000Source | 10,594,000Source | 15,673,000Source | 9,712,000Source | 9,902,000Source | 17,178,000Source | 26,834,000Source |
| Property, Plant and Equipment, NetUSD | 3,348,000Source | 5,268,000Source | 2,175,000Source | 3,468,000Source | 7,947,000Source | 3,097,000Source | 3,586,000Source | 8,104,000Source | 2,141,000Source | 3,695,000Source | 8,213,000Source | 9,419,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 1,869,000Source | 1,182,000Source | 4,879,000Source | 1,803,000Source | 1,181,000Source | 1,997,000Source | 1,720,000Source | 1,179,000Source | 5,101,000Source | 1,616,000Source | 1,170,000Source | 917,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 470,000Source | 1,378,000Source | 1,105,000Source | 1,546,000Source | 3,026,000Source | 454,000Source | 1,824,000Source | 1,723,000Source | 900,000Source | 1,198,000Source | 3,196,000Source | 10,460,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 49,000Source | 92,000Source | 41,000Source | 44,000Source | 137,000Source | 87,000Source | 28,000Source | 225,000Source | 12,000Source | 39,000Source | 107,000Source | 125,000Source |
| Inventory, NetUSD | 1,433,000Source | 1,925,000Source | 658,000Source | 1,510,000Source | 2,636,000Source | 1,349,000Source | 1,510,000Source | 2,641,000Source | 640,000Source | 1,540,000Source | 2,651,000Source | 3,548,000Source |
| Assets, CurrentUSD | 3,051,000Source | 3,583,000Source | 2,004,000Source | 4,250,000Source | 6,117,000Source | 2,153,000Source | 4,407,000Source | 5,078,000Source | 1,790,000Source | 3,705,000Source | 6,466,000Source | 15,111,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 398,000Source | 188,000Source | 175,000Source | 434,000Source | 220,000Source | 212,000Source | 325,000Source | 262,000Source | 200,000Source | 208,000Source | 358,000Source | 978,000Source |
| Operating Lease, Right-of-Use AssetUSD | 129,000Source | 227,000Source | 13,000Source | 161,000Source | 263,000Source | 16,000Source | 193,000Source | 295,000Source | 11,000Source | 198,000Source | 326,000Source | 450,000Source |
| Other Assets, NoncurrentUSD | 681,000Source | 999,000Source | 672,000Source | 687,000Source | 998,000Source | 680,000Source | 688,000Source | 1,017,000Source | 669,000Source | 688,000Source | 1,003,000Source | 937,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 2,819,000Source | 2,206,000Source | 1,651,000Source | 2,992,000Source | 2,408,000Source | 1,865,000Source | 2,714,000Source | 2,471,000Source | 2,289,000Source | 2,581,000Source | 2,267,000Source | 2,942,000Source |
| Commitments and ContingenciesUSD | 0Source | — | 0Source | 0Source | — | 0Source | 0Source | — | 0Source | 0Source | — | — |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Retained Earnings (Accumulated Deficit)USD | -119,589,000Source | -110,780,000Source | -122,828,000Source | -117,760,000Source | -105,191,000Source | -122,343,000Source | -116,043,000Source | -102,740,000Source | -124,890,000Source | -113,665,000Source | -100,665,000Source | -89,159,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -3,459,000Source | -3,425,000Source | -4,854,000Source | -3,441,000Source | -3,443,000Source | -3,499,000Source | -3,426,000Source | -3,380,000Source | -5,701,000Source | -3,423,000Source | -3,389,000Source | -2,968,000Source |
| Stockholders' Equity Attributable to ParentUSD | 6,259,000Source | 9,053,000Source | 8,092,000Source | 7,377,000Source | 14,098,000Source | 6,078,000Source | 7,880,000Source | 13,202,000Source | 7,423,000Source | 7,321,000Source | 14,911,000Source | 23,892,000Source |
| Liabilities and EquityUSD | 9,078,000Source | 11,259,000Source | 9,743,000Source | 10,369,000Source | 16,506,000Source | 7,943,000Source | 10,594,000Source | 15,673,000Source | 9,712,000Source | 9,902,000Source | 17,178,000Source | 26,834,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 2,657,000Source | 1,936,000Source | 1,514,000Source | 2,802,000Source | 2,106,000Source | 1,725,000Source | 2,489,000Source | 2,131,000Source | 2,156,000Source | 2,340,000Source | 1,898,000Source | 2,441,000Source |
| Operating Lease, Liability, CurrentUSD | 124,000Source | 124,000Source | 9,000Source | 134,000Source | 130,000Source | 62,000Source | 133,000Source | 129,000Source | 9,000Source | 124,000Source | 133,000Source | 123,000Source |
| Accounts Payable, CurrentUSD | 835,000Source | 648,000Source | 628,000Source | 768,000Source | 549,000Source | 933,000Source | 771,000Source | 672,000Source | 1,014,000Source | 773,000Source | 530,000Source | 981,000Source |
| Operating Lease, Liability, NoncurrentUSD | 12,000Source | 115,000Source | 5,000Source | 35,000Source | 146,000Source | 7,000Source | 69,000Source | 179,000Source | 2,000Source | 84,000Source | 207,000Source | 341,000Source |
| Other Liabilities, NoncurrentUSD | 16,000Source | 17,000Source | 0Source | 20,000Source | 17,000Source | 0Source | 20,000Source | 21,000Source | 0Source | 20,000Source | 21,000Source | 16,000Source |
| Additional Financial Items | ||||||||||||
| Accounts Receivable, after Allowance for Credit LossUSD | 49,000Source | 92,000Source | 41,000Source | 44,000Source | 137,000Source | 87,000Source | 28,000Source | 225,000Source | 12,000Source | 39,000Source | 107,000Source | 124,000Source |
| Accrued Liabilities, CurrentUSD | 1,822,000Source | 1,288,000Source | 886,000Source | 2,034,000Source | 1,557,000Source | 792,000Source | 1,718,000Source | 1,459,000Source | 1,142,000Source | 1,567,000Source | 1,368,000Source | 1,457,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 134,000Source | 138,000Source | 132,000Source | 135,000Source | 139,000Source | 133,000Source | 136,000Source | 140,000Source | 131,000Source | 137,000Source | 141,000Source | 144,000Source |
| Short-term InvestmentsUSD | — | — | 25,000Source | — | 98,000Source | — | — | 227,000Source | 38,000Source | 0Source | 154,000Source | 0Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -1,829,000Source | -5,589,000Source | -1,821,000Source | -1,717,000Source | -1,599,000Source | -2,378,000Source | -7,121,000Source | -13,000,000Source | -11,506,000Source | -15,016,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 141,000Source | 162,000Source | 618,000Source | 637,000Source | 657,000Source | 651,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 4,700,000Source | 4,600,000Source | 4,300,000Source | 4,600,000Source | 5,500,000Source | 7,000,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 53,000Source | -11,000Source | 8,000Source | 25,000Source | -5,000Source | -50,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -11,000Source | -30,000Source | -180,000Source | -1,008,000Source | -897,000Source | -1,930,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 51,000Source | -2,000Source | 106,000Source | 243,000Source | -451,000Source | 504,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -1,407,000Source | -1,752,000Source | -4,795,000Source | -5,199,000Source | -7,047,000Source | -7,462,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 580,000Source | -131,000Source | -442,000Source | -317,000Source | -235,000Source | -742,000Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | — | — | — | — | — | — | — | — | — | — | 154,000Source | 0Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 8,000Source | 38,000Source | 112,000Source | 138,000Source | 310,000Source | 207,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 851,000Source | 2,507,000Source | 4,451,000Source | 3,524,000Source | 100,000Source | 4,142,000Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | — | — | 3,000Source | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 49,000Source | 626,000Source | -793,000Source | -1,998,000Source | -7,264,000Source | -4,088,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 470,000Source | 1,378,000Source | 1,105,000Source | 1,546,000Source | 454,000Source | 1,824,000Source | 405,000Source | 1,198,000Source | 3,196,000Source | 10,460,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 1,000Source | 1,000Source | — | — | — | 0Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | 452,000Source | 402,000Source | 1,640,000Source | 1,773,000Source | 2,843,000Source | 2,197,000Source |
| Amortization of Intangible AssetsUSD | — | — | 17,000Source | 20,000Source | 14,000Source | 20,000Source | 14,000Source | 20,000Source | — | 74,000Source | 57,000Source | 24,000Source |
| DepreciationUSD | — | — | 144,000Source | 140,000Source | 105,000Source | 145,000Source | 127,000Source | 142,000Source | 567,000Source | 563,000Source | 600,000Source | 627,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | 25,000Source | 44,000Source | -39,000Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 430,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Inventory Write-downUSD | — | — | — | — | — | — | 3,000Source | 26,000Source | 217,000Source | 1,000,000Source | 376,000Source | 252,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,829,000Source | -5,589,000Source | -1,821,000Source | -1,717,000Source | -1,599,000Source | -2,378,000Source | -7,122,000Source | -13,000,000Source | -11,506,000Source | -15,016,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 49,000Source | 32,000Source | 1,078,000Source | 43,000Source | 306,000Source | 18,000Source | 325,000Source | 143,000Source | 65,000Source | 461,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | — | — | 0Source | — | — | 0Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 852,000Source | 2,508,000Source | 4,454,000Source | 3,027,000Source | — | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | — | — | — | — | 289,000Source |
| Stock or Unit Option Plan Expense | — | — | — | — | — | — | —Source | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 257,000Source | 204,000Source | 191,000Source | 412,000Source | 328,000Source | 272,000Source | 1,271,000Source | 1,345,000Source | 911,000Source | 397,000Source |
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Selling, General and Administrative ExpenseUSD | — | — | 1,130,000Source | 2,228,000Source | 1,410,000Source | 1,041,000Source | 1,208,000Source | 1,670,000Source | 4,410,000Source | 6,758,000Source | 8,552,000Source | 13,292,000Source |
| Operating Income (Loss)USD | — | — | -1,878,000Source | -2,998,000Source | -2,899,000Source | -1,760,000Source | -1,905,000Source | -2,396,000Source | -7,446,000Source | -9,798,000Source | -11,571,000Source | -15,428,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 49,000Source | 32,000Source | 1,078,000Source | 43,000Source | 306,000Source | 18,000Source | 325,000Source | 143,000Source | 65,000Source | 461,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -1,829,000Source | -5,589,000Source | -1,821,000Source | -1,717,000Source | -1,599,000Source | -2,378,000Source | -7,121,000Source | -13,000,000Source | -11,506,000Source | -15,016,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,829,000Source | -5,589,000Source | -1,821,000Source | -1,717,000Source | -1,599,000Source | -2,378,000Source | -7,122,000Source | -13,000,000Source | -11,506,000Source | -15,016,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.02Source | -0.09Source | -0.02Source | -0.02Source | -0.02Source | -0.03Source | -0.09Source | — | — | — |
| Earnings Per Share, DilutedUSD per share | — | — | -0.02Source | -0.09Source | -0.02Source | -0.02Source | -0.02Source | -0.03Source | -0.09Source | — | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 77,633,004Source | 63,725,084Source | 90,457,910Source | 76,007,129Source | 83,027,117Source | 72,813,538Source | 76,517,175Source | 58,839,868Source | 52,576,258Source | 49,991,631Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 77,633,004Source | 63,725,084Source | 90,457,910Source | 76,007,129Source | 83,027,117Source | 72,813,538Source | 76,517,175Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 17,000Source | 20,000Source | 14,000Source | 20,000Source | 14,000Source | 20,000Source | — | 74,000Source | 57,000Source | 24,000Source |
| Gross ProfitUSD | — | — | 104,000Source | 133,000Source | 99,000Source | 198,000Source | 154,000Source | 163,000Source | 619,000Source | 733,000Source | 442,000Source | 194,000Source |
| Interest Expense, DebtUSD | — | — | — | — | — | — | 1,000Source | 1,000Source | 5,000Source | 5,000Source | 5,000Source | 5,000Source |
| Research and Development ExpenseUSD | — | — | 852,000Source | 903,000Source | 1,588,000Source | 917,000Source | 851,000Source | 889,000Source | 3,655,000Source | 3,773,000Source | 3,461,000Source | 2,330,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | — | — | — | — | 289,000Source |
Filing attachments
igcex99-1.htm · 8-K · 2026-07-14
EX-99.1 2 igcex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Advancing Alzheimer’s Care. Improving Lives. NYSE American: IGC SAFE HARBOR : Forward - Looking Statements and Important Cautionary Information: This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward - looking statements include statements regarding the timing, conduct and results of the CALMA Phase 2 trial; the safety and efficacy of IGC - AD1; regulatory …
Read attachment ↗igcex99-1.htm · 8-K · 2026-03-30
EX-99.1 2 igcex99-1.htm EXHIBIT 99.1 Exhibit 99.1 IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness POTOMAC, MARYLAND - March 30, 2026 - IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company developing therapeutics for Alzheimer’s disease, today announced a strategic 12-part national media partnership with New to The Street, a leading financial media platform known for its integrated…
Read attachment ↗igcex99-1.htm · 8-K · 2025-11-14
EX-99.1 2 igcex99-1.htm EXHIBIT 99.1 Exhibit 99.1 IGC Pharma Inc UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Note 1 - Transaction Overview On September 29, 2025, Holi Hemp LLC (“HHP”), a wholly owned subsidiary of IGC Pharma, Inc. (the “Company”), completed the disposition of certain manufacturing equipment, leasehold assets, and inventory located at its Vancouver, Washington facility (the “Vancouver Facility”) pursuant to a Sale of Assets and Manufacturing Agreement …
Read attachment ↗igcex99-1.htm · 8-K · 2025-10-14
EX-99.1 2 igcex99-1.htm EXHIBIT 99.1 Exhibit 99.1 IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders POTOMAC, MARYLAND - October 10, 2025 - IGC Pharma, Inc. (“IGC Pharma”, “IGC”, or the “Company”) (NYSE American: IGC) a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer’s disease, today announced results from its Annual Meeting of Stockholders scheduled for and convened on October 10, 2025 (the “Annual Meeting”). All proposals…
Read attachment ↗igcex99-1.htm · 8-K · 2025-06-17
EX-99.1 2 igcex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Date: June 16, 2025 NYSEAmerican: IGC 1 NYSE AMERICAN: IGC - Service to humanity - Safe Harbor The information presented in these slides includes forward - looking statements regarding the business prospects of IGC Pharma, Inc. ("IGC" or the "Company"). These forward - looking statements are based on management's current expectations as of the date of this presentation and are subject to a number of risks and uncertainties, many of which ar…
Read attachment ↗